A phase I study identified IL-15 superagonist complex ALT-803 as a safe agent in the treatment of elderly AML patients who relapsed after HCT and the potential efficacy is expected to be reported (NCT01885897) [198]. The gene discussed is IL15; the disease is acute myeloid leukemia.